富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦(Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate) - 药物靶点：HIV-1 integrase x RT_在研适应症：HIV感染，乙型肝炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

B/F/TAF、BIC/FTC/TAF、Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate

+ [12]

靶点

HIV-1 integrase x RT

作用机制

HIV-1 integrase抑制剂(HIV整合酶抑制剂)、RT抑制剂(逆转录酶抑制剂)

治疗领域

免疫系统疾病感染泌尿生殖系统疾病+ [1]

在研适应症

HIV感染乙型肝炎

非在研适应症-

原研机构

Gilead Sciences, Inc.

在研机构

Gilead Sciences Ireland Unlimited Co.

Gilead Sciences, Inc.Gilead Sciences Ireland UC

+ [1]

非在研机构

Merck Sharp & Dohme Corp.

最高研发阶段批准上市

首次获批日期

美国 (2018-02-07),

HIV感染

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C25H33N6O9P

InChIKeyMEJAFWXKUKMUIR-FHPNUNMMSA-N

CAS号1392275-56-7

查看全部结构式(3)

关联

95

项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的临床试验

NCT06337032 / Not yet recruiting临床4期

An Open-label, Single-arm Study to Provide Continued Access to Study Drug to Participants Who Have Completed Pediatric Clinical Studies Involving Gilead HIV Treatments

The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events.
The primary objectives of this study are as follows:
To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment.
To evaluate the safety of the study drug(s) in participants with HIV-1.

开始日期2024-09-01

申办/合作机构

Gilead Sciences, Inc.

NCT06393387 / Not yet recruitingN/AIIT

Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States (REVIVE Study)

This real-world retrospective study describes the clinical efficacy of 2DR (DOVATO® (DTG/3TC)) versus 3DR (BIKTARVY® (BIC/F/TAF)) in PWH, including those with at least 2 social determinants of health indicators, across a multi clinic infectious disease organization in the Southeast United States

开始日期2024-06-01

申办/合作机构-

NCT06375304 / Not yet recruiting临床4期IIT

Antiretroviral Speed Access Program Switch Study (The ASAP Switch Study) - A Pilot Study to Switch ART-experienced and Newly-referred Migrant People With HIV to B/F/TAF

This project builds on our experience with the ASAP Study (McGill University Health Centre research ethics board: MP-37-2020-4911). The goal of this study is to better understand the experience of migrant people with Human Immunodeficiency Virus (HIV) of having their treatment switched to Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). In other words, the investigators want to evaluate how feasible and acceptable this switch is, and how participants will take B/F/TAF (fidelity) and remain on it. The investigators also want to know more about migrant people with HIV's experience of care; namely, how often they see their HIV specialist or other healthcare professionals, and their healthcare coverage (the type of insurance that they have).

开始日期2024-05-01

申办/合作机构-

100 项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的临床结果

登录后查看更多信息

100 项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的转化医学

登录后查看更多信息

100 项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的专利（医药）

登录后查看更多信息

79

项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的文献（医药）

2024-01-01·Heliyon

Comparison of the efficacy of combined budesonide and fexofenadine versus combined fluticasone propionate and fexofenadine on the expression of class-4 semaphorins and their receptors in the peripheral blood cells of patients with allergic rhinitis

Article

作者: Salari, Farhad ; Rezaei Varmaziar, Fatemeh ; Rezaiemanesh, Alireza ; Gorgin Karaji, Ali ; Falahi, Sara ; Feizollahi, Parisa ; Asadi, Gelayol ; Rajabinejad, Misagh ; Faryadi, Elham

Background:

Allergic rhinitis (AR) is a common immunoglobulin (Ig) E-mediated disease. This study aimed to evaluate the gene expression levels of class 4 semaphorins and their receptors in AR patients before and after treatment with budesonide and fexofenadine (B/F) compared to fluticasone propionate and fexofenadine (FP/F).

Methods:

In this study, 29 AR patients (age 34.4 ± 1.2 years, 18 men and 11 women) were treated with B/F, and 24 AR patients (age 32.8 ± 1.9 years, 15 men and 9 women) were treated with FP/F for one month. Before and after treatment, peripheral blood samples were taken from patients. The expression levels of SEMA4A, SEMA4C, SEMA4D, Plexin-B2, and Plexin-D1 genes were measured using the qPCR method. In addition, the serum levels of IgE were measured using an enzyme-linked immunosorbent assay (ELISA).

Results:

The expression levels of SEMA4A (P = 0.011), 4C (P = 0.017), Plexin-B2 (P = 0.0005), and Plexin-D1 (P = 0.008) remarkably increased in AR patients treated with B/F. Our results show a significant reduction in the gene expression levels of SEMA4A (P = 0.002), 4C (P = 0.014), 4D (P = 0.003), Plexin-B2 (P = 0.033), and Plexin-D1 (P = 0.035) after treatment with FP/F. The serum levels of IgE increased in FP/F treated group (P = 0.017) and conversely decreased in the treated group with B/F (P = 0.019). Moreover, the percentages of eosinophils were reduced in both FP/F and B/F groups (P = 0.015 and P = 0.0001, respectively).

Conclusion:

In conclusion, concomitant use of fexofenadine and fluticasone propionate reduced SEMA4A, 4C, 4D, Plexin-B2, and Plexin-D1, while the SEMA4A, 4C, Plexin-B2, and Plexin-D1 gene expression levels were increased in the patient group treated with B/F.

2024-01-01·AIDS

A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV

Article

作者: Shang, Justin ; Avihingsanon, Anchalee ; Hindman, Jason T ; Arora, Priyanka ; Xiao, Deqing ; Davis, Maggie ; Zhang, Haeyoung ; Girish, Sandhya ; Palaparthy, Ramesh ; Marathe, Dhananjay D ; Lin, Ludwig

Objective::

The objective of this study was to assess the pharmacokinetics, safety, and efficacy and confirm the dose of once-daily bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF; B/F/TAF) during pregnancy.

Design::

An open-label, multicenter, single-arm, phase 1b study (NCT03960645) was conducted in 33 virologically suppressed pregnant women with HIV-1.

Methods::

Participants received B/F/TAF (50/200/25 mg) from the second or third trimester through ∼16 weeks postpartum. Steady-state maternal plasma pharmacokinetic samples were collected at the second and third trimesters and 6 and 12 weeks postpartum for BIC, FTC, and TAF. Neonates (n = 29) were followed from birth to 4–8 weeks with sparse washout pharmacokinetic sampling for BIC and TAF. The proportion of participants with HIV-1 RNA less than 50 copies/ml at delivery (missing = excluded) was evaluated.

Results::

Mean areas under the concentration–time curve over the dosing interval (AUCtau) for BIC, FTC, and TAF were lower during pregnancy versus postpartum but were closer to AUCtau values for nonpregnant adults with HIV reported in other studies. Geometric least-squares mean ratios for BIC, FTC, and TAF AUCtau during pregnancy versus postpartum ranged from 41 to 45%, 64 to 69% and 57 to 78%, respectively. Mean BIC trough concentrations during pregnancy were more than 6.5-fold greater than the protein-adjusted 95% effective concentration. In neonates, the median BIC half-life was 43 h. Virologic suppression was maintained in all adult participants throughout the study, with no virologic failure or treatment-emergent resistance to HIV-1, no discontinuations because of adverse events, and no perinatal transmission.

Conclusion::

Exposures to BIC, FTC, and TAF were lower during pregnancy than postpartum. However, mean BIC trough concentrations were maintained at levels indicative of efficacious exposure, and FTC/TAF data were concordant with published literature in this population. Pharmacokinetic and safety data, combined with maintenance of robust virologic suppression, suggest that once-daily B/F/TAF without dose adjustment is appropriate during pregnancy.

2023-11-20·Chinese Medical Journal

Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1

Article

作者: Wang, Yanhao ; Deng, Yiming ; Wei, Yinghua ; Xu, Ruhong ; He, Lixia ; Li, Jin ; Zhong, Huijun ; Wen, Li

Abstract:

Background::

Dual regimen dolutegravir (DTG) plus lamivudine (3TC) has demonstrated non-inferior efficacy compared to DTG-based three-drug regimens (3DRs), yet directly comparative data regarding the efficacy and safety of DTG + 3TC and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for therapy-naïve people with human immunodeficiency virus (HIV)-1 (PWH) are still limited. We aimed to assess the antiviral potency and safety profiles of DTG + 3TC vs. B/F/TAF based on antiretroviral therapy (ART)-naïve PWH in China.

Methods::

This retrospective multicenter study enrolled PWH initiating ART with DTG + 3TC or B/F/TAF from 2020 to 2022 in Guangdong and Guangxi. We analyzed response rates based on target not detected (TND) status using intention-to-treat (ITT) analysis. Subgroups were formed based on baseline viral load (VL) (<100,000 vs. ≥100,000 copies/mL) and CD4+ cell count (<200 vs. ≥200 cell/µL). Median time to TND VL was assessed by Kaplan–Meier method. We also measured changes from baseline in CD4+ cell counts, CD4/CD8 ratio, lipid parameters, weight, creatinine (Cr), estimated glomerular filtration rate (eGFR), and drug-related adverse effects (DRAEs).

Results::

We enrolled 280 participants, including 137 (48.9%) on DTG + 3TC and 143 (51.1%) on B/F/TAF. At week 48, 96.4% (132/137) on DTG+3TC and 100% (143/143) on B/F/TAF achieved TND (P = 0.064). At week 12, TND responses were higher with B/F/TAF (78.3% [112/143]) than DTG+3TC (30.7% [42/137]) (P <0.001). This trend held across subgroups. B/F/TAF achieved TND faster (12 weeks) than DTG+3TC (24 weeks) (P <0.001). No differences were seen in CD4+ cell count and CD4/CD8 ratio, except in the high-VL subgroup, where B/F/TAF showed better recovery. DRAEs were significantly lower with B/F/TAF (4.9% [7/143]) than with DTG + 3TC (13.1% [18/137]) (P = 0.016). Lipid parameters, body weight, and Cr increased in both groups over 48 weeks, with DTG+3TC showing a more favorable effect on triglycerides, high-density lipoprotein (HDL) cholesterol, and weight gain.

Conclusions::

In this real-life study, B/F/TAF led to a faster viral decline and fewer DRAEs compared to DTG+3TC. No significant difference was observed in the TND rate at week 48, regardless of baseline VL and CD4+ cell count. CD4+ recovery was superior for B/F/TAF in participants with high VL. The DTG + 3TC regimen had less impact on metabolic changes than B/F/TAF.

167

项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的新闻（医药）

2024-04-29

·Pharmaceutical Technology

Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data

Gilead’s Biktarvy has previously been approved by the US FDA as HIV treatment in both adult and paediatric (weighing at least 14kg) populations. Image Credit: Michael Vi / Shutterstock. Gilead Sciences has received a US Food and Drug Administration (FDA) approval for the label expansion of its human immunodeficiency virus -1 (HIV-1) fixed dose combination therapy, Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg). The therapy is approved in pregnant patients in their second and third trimesters and up to 16 weeks following delivery (postpartum) with suppressed viral loads of HIV-1. The FDA first approved Biktarvy as a complete regimen for treating HIV-1 in adults who either have no antiretroviral treatment history or as a replacement for the current antiretroviral regimen in those who are virologically suppressed, in 2018. The FDA label expansion was based on the data from an open-label Phase Ib trial (study 5310). The single-arm study evaluated the pharmacokinetics, safety, and efficacy of Biktarvy in 32 pregnant patients with suppressed viral loads of HIV-1. All the participants maintained viral suppression during pregnancy and through 18 weeks postpartum, with lower plasma exposures observed during pregnancy compared to postpartum. All 29 newborn participants had negative or nondetectable HIV-1 polymerase chain reaction (PCR) results at birth and/or at four to eight weeks postbirth. In addition, the trial did not identify any new safety or tolerability concerns for people who use Biktarvy during pregnancy and postpartum. The overall incidence and types of adverse events observed were consistent with those expected for the population studied, as per Gilead. See Also: Accord BioPharma’s HERCESSI secures FDA approval Biktarvy is recommended as an alternative complete regimen for use in pregnancy and for people who are trying to conceive by the US Department of Health and Human Services (DHHS) perinatal guidelines. Biktarvy is a top revenue-generating therapy in Gilead’s portfolio and pulled in $2.9bn in sales in Q1 this year, as per the company’s financials. The sales for the therapy are expected to increase to $15.5bn in 2030, as per GlobalData analysis. GlobalData is the parent company of Pharmaceutical Technology . Another HIV therapy in Gilead’s portfolio is Sunlenca (lenacapavir), an FDA-approved multidrug-resistant HIV treatment . The company is evaluating Sunlenca in combination with Merck & Co’s islatravir as a long-acting HIV treatment for virologically suppressed people living with HIV.

上市批准临床1期临床结果临床2期

2024-04-26

·EndPoints

FDA greenlights label update to Gilead's Biktarvy to include more data in pregnant people

The FDA on Friday approved a label update on Biktarvy, Gilead’s blockbuster HIV drug, to include more data on the drug’s safety and efficacy for pregnant people with HIV. The additional data reflected on the label are supported by positive results from Gilead’s Study 5310, which evaluated Biktarvy in pregnant people with HIV-1 who have suppressed viral loads, meaning that they have a low level of virus in their bodies. The study evaluated people in their second and third trimesters through a median of 16 weeks postpartum. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

临床结果上市批准临床研究

2024-04-26

·BioSpace

Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline

Pictured: Gilead sign outside its corporate headquarters in Silicon Valley/iStock, Sundry Photography Gilead Sciences on Thursday released its first-quarter 2024 earnings results, touting a 5% year-on-year increase in total revenue, driven by the strong performance of its HIV, cancer and liver disease businesses. In Q1, Gilead posted nearly $6.69 billion in earnings, up from more than $6.35 billion during the same period the prior year. The pharma’s HIV franchise, anchored by Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), remained its strongest unit with quarterly sales growing 4% to more than $4.34 billion. Biktarvy was Gilead’s top-performing asset bringing in nearly $2.95 billion worldwide, followed by the antiviral Veklury (remdesivir) which took a 3% sales hit but nevertheless brought in $555 million. “Gilead delivered another strong quarter of revenue growth … in our base business driven by HIV, Oncology and Liver Diseases,” CEO Daniel O’Day said in a statement, adding that the pharma is looking forward to a year of promising pipeline updates, particularly regarding its long-acting HIV and cancer programs. Despite the positive revenue growth, Gilead reported that it is diluted earnings per share (EPS) dropped $3.34 in the first quarter, which was primarily due to “an acquired in-process research and development charge of $3.9 billion, or $3.14 per share, related to the acquisition of CymaBay therapeutics.” In February 2024, Gilead announced that it was buying CymaBay for $4.3 billion, or $32.50 per share, in cash. The acquisition gave Gilead ownership of seladelpar, which is being developed for primary biliary cholangitis (PBC). Gilead CFO Andy Dickinson in a Thursday investor call said that “while the transaction will be dilutive to our EPS this year, we expect the deal to be breakeven to earnings in 2025, and significantly accretive in 2026 onwards.” Seladelpar is expected to be a strong contributor to Gilead’s ledger this year and beyond. The FDA is currently reviewing seladelpar with its decision due on August 14, 2024, and the company is working to make the drug available shortly after its potential approval. “Following its launch in 2024, we expect seladelpar to contribute modestly to sales and more meaningfully in 2025 and beyond,” CCO Johanna Mercier said in the investor call, adding that the drug candidate—a selective PPAR delta agonist—has “the potential to be best-in-class with a differentiated clinical profile” and could fulfill a significant unmet need in PBC. Besides seladelpar, Gilead is also looking forward to readouts for its HIV treatment Sunlenca (lenacapavir) for pre-exposure prophylaxis. A Phase III update is expected in the second half of this year, with a potential launch as early as 2025. Gilead also announced Thursday that it has finally discontinued the development of the anti-CD47 antibody magrolimab, which has suffered a series of clinical holds in recent months. The pharma also ended the development of its CAR-T therapy Tecartus (brexucabtagene autoleucel) for rare B-cell malignancies, as well as another early-stage cell therapy for relapsed/refractory acute myeloid leukemia. Gilead also scrapped two studies of the Arcus-partnered domvanalimab in non-small cell lung cancer. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

并购免疫疗法临床2期细胞疗法临床3期

100 项与富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J05AR	-

研发状态

适应症	最高研发状态	国家/地区	公司
HIV感染	批准上市	中国更多	Gilead Sciences Ireland Unlimited Co. 更多
乙型肝炎	临床3期	泰国更多	Gilead Sciences, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06177574 (Pubmed)	临床4期	HIV感染一线	208	Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)	鹹夢願鹽憲憲艱蓋淵簾(淵齋範齋選願積獵網積) = 鬱願憲築糧遞積構顧顧鹹襯選鹽蓋齋選繭顧範 (夢鏇製餘醖網壓窪鑰顧 ) 更多	-	2024-04-02
NCT06019273 (Pubmed)	N/A	HIV感染	-	Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)	襯簾網壓淵願膚餘鑰齋(網觸膚鑰艱襯壓艱願醖) = 鹽齋窪壓鏇鬱築遞鏇築餘鏇淵鏇夢製餘鬱顧憲 (窪製觸膚簾憲鹽遞觸構, 0.75)	-	2024-03-15
NCT06019273 (Pubmed)	N/A	HIV感染	-	Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)	襯簾網壓淵願膚餘鑰齋(網觸膚鑰艱襯壓艱願醖) = 鹹艱衊鬱獵鏇衊廠顧築餘鏇淵鏇夢製餘鬱顧憲 (窪製觸膚簾憲鹽遞觸構, 0.62)	-	2024-03-15
NCT03547908 (ALLIANCE, Corporate Publications) 人工标引	临床3期	合并感染 \| 乙型肝炎 \| HIV感染	243	Biktarvy	築襯顧窪襯鹹築淵鬱願(淵築蓋網夢艱淵繭鏇淵) = upper respiratory tract infection (19.8% vs. 14.8%), COVID-19 (38% vs. 36.1%), pyrexia (12.4% vs. 13.1%), ALT increase (8.3% vs. 12.3%), and nasopharyngitis (12.4% vs. 6.6%). 構醖餘築繭範鏇網獵製 (餘網憲鑰窪鑰獵構鑰構 )	积极	2024-03-06
NCT03547908 (ALLIANCE, Corporate Publications) 人工标引	临床3期	合并感染 \| 乙型肝炎 \| HIV感染	243	dolutegravir+emtricitabine+tenofovir disoproxil fumarate		积极	2024-03-06
NCT04734652 (INSIGHT, BusinessWire) 人工标引	临床2期	合并感染 \| 结核 \| HIV感染	-	Biktarvy	願憲夢艱憲蓋積顧艱餘(網網選觸壓窪製鬱遞顧) = 觸襯選餘遞膚鏇夢廠積鹽鏇鏇鹹鹹遞艱淵製襯 (網顧淵窪鹹簾醖網壓願 )	积极	2024-03-06
NCT04734652 (INSIGHT, BusinessWire) 人工标引	临床2期	合并感染 \| 结核 \| HIV感染	-	dolutegravir+lamivudine+tenofovir disoproxil fumarate	願憲夢艱憲蓋積顧艱餘(網網選觸壓窪製鬱遞顧) = 鏇選衊醖鏇遞積鹹醖獵鹽鏇鏇鹹鹹遞艱淵製襯 (網顧淵窪鹹簾醖網壓願 )	积极	2024-03-06
NCT04538040 (CTgov)	临床4期	HIV感染	20	Doravirine+Bictegravir/emtricitabine/tenofovir alafenamide	鹹簾膚鏇築艱壓膚糧願(製艱淵築鑰淵獵夢選廠) = 範鑰糧淵蓋願夢艱網觸蓋構餘簾遞窪繭壓壓壓 (糧鹽壓鹹築衊壓築蓋顧, 壓淵醖壓簾糧積繭選鏇 ~ 網觸鬱範壓襯選範糧夢) 更多	-	2024-03-05
NCT04233879 (CTgov)	临床3期	HIV感染	599	DOR/ISL+Placebo to BIC/FTC/TAF (Group 1: DOR/ISL)	觸觸獵膚鏇窪鬱醖餘壓(範獵膚醖廠獵壓壓糧衊) = 簾築壓簾醖膚築廠範觸齋積壓構鹽淵繭醖憲積 (築獵齋憲糧遞夢範餘築, 憲遞鏇窪獵積蓋獵糧醖 ~ 網鹽鬱餘衊淵襯壓獵壓) 更多	-	2023-11-21
NCT04233879 (CTgov)	临床3期	HIV感染	599	Placebo to DOR/ISL+BIC/FTC/TAF (Group 2: BIC/FTC/TAF)	觸觸獵膚鏇窪鬱醖餘壓(範獵膚醖廠獵壓壓糧衊) = 繭餘獵簾範鹽憲糧鹹遞齋積壓構鹽淵繭醖憲積 (築獵齋憲糧遞夢範餘築, 蓋醖鏇廠鏇壓窪選夢壓 ~ 廠鹹鬱齋廠繭遞觸夢醖) 更多	-	2023-11-21
NCT03797014 (CTgov)	临床4期	HIV感染 \| 合并感染 \| 乙型肝炎	28	B/F/TAF	築鹽窪獵餘觸淵網壓艱(膚襯醖淵糧網觸願蓋鑰) = 襯夢選製鏇觸鹽淵範餘獵鹽壓壓選膚齋積網製 (餘網壓願膚窪簾蓋網廠, 餘鹹齋鏇築壓顧獵鏇遞 ~ 鑰齋網鹹製壓鏇鹽蓋鹹) 更多	-	2023-07-18
NCT04860505 (CTgov)	临床4期	性传播疾病	20	Doxycycline+Biktarvy	積齋醖簾鑰獵鑰製鹽衊(鏇襯廠構糧積構憲鹽艱) = 觸積簾網壓鏇醖構糧膚廠醖築顧淵鬱齋顧鬱鹹 (夢廠糧襯獵願鏇網顧鑰, 製淵餘鹽範廠膚築壓選 ~ 糧繭網願築獵願窪網夢) 更多	-	2023-05-23
NCT03547908 (CTgov)	临床3期	乙型肝炎 \| HIV感染	244	Placebo to match DTG+B/F/TAF	願膚蓋鬱選壓鹹鑰衊製(鑰顧廠襯醖遞觸餘鏇鑰) = 衊遞觸壓鹽繭鑰衊膚繭鬱衊築繭範膚繭淵構淵 (夢淵糧築餘網衊夢顧襯, 鏇齋簾遞遞觸範簾憲糧 ~ 繭襯鬱膚艱積夢觸鹽餘) 更多	-	2023-03-15
NCT03656783 (CTgov)	临床3期	HIV感染	25	Biktarvy	窪壓繭網鏇獵遞鹽築壓(鹽簾蓋製糧簾遞鑰顧範) = 選願鏇鬱憲構鹹遞膚膚鬱繭齋衊夢鏇範選鏇襯 (簾衊鹽衊糧艱蓋憲鬱製, 淵窪齋膚糧壓窪簾壓構 ~ 簾蓋獵夢齋範窪壓遞製) 更多	-	2023-02-08